Literature DB >> 6977636

Physiologic model for the pharmacokinetics of 2'deoxycoformycin in normal and leukemic mice.

F G King, R L Dedrick.   

Abstract

A flow-limited physiologic mathematical model has been developed to describe the time course of 2'deoxycoformycin (2'dCF) concentrations in the plasma and tissues of mice following iv and ip doses. Urinary excretion is modeled as a linear involving filtration and secretion, since kidney clearance exceeded estimated glomerular filtration rate. Intracellular binding is described as the sum of linear nonspecific binding plus strong saturable binding to adenosine deaminase. Pharmacokinetic parameters are determined by a sequential optimization scheme in which each tissue is studied by means of a hybrid model. The model has been used to predict pharmacokinetic behaviour of 2'dCF in both normal and leukemic mice, and model simulations are compared with published data.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6977636     DOI: 10.1007/BF01061024

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  21 in total

1.  A STUDY OF THE TISSUE DISTRIBUTION OF ADENOSINE DEAMINASE IN SIX MAMMAL SPECIES.

Authors:  T G BRADY; C I O'DONOVAN
Journal:  Comp Biochem Physiol       Date:  1965-01

2.  Use of microbiologic and enzymatic assays in studies on the disposition of 2'-deoxycomformycin in the mouse.

Authors:  W R McConnell; W J Suling; L S Rice; M Shannon; D L Hill
Journal:  Cancer Treat Rep       Date:  1978-08

3.  Distribution of anticancer agents in spontaneous animal tumors. I. Regional blood flow and methotrexate distribution in canine lymphosarcoma.

Authors:  J A Straw; M M Hart; P Klubes; D S Zaharko; R L Dedrick
Journal:  J Natl Cancer Inst       Date:  1974-04       Impact factor: 13.506

4.  Methotrexate pharmacokinetics.

Authors:  K B Bischoff; R L Dedrick; D S Zaharko; J A Longstreth
Journal:  J Pharm Sci       Date:  1971-08       Impact factor: 3.534

5.  Tight-binding inhibitors--IV. Inhibition of adenosine deaminases by various inhibitors.

Authors:  R P Agarwal; T Spector; R E Parks
Journal:  Biochem Pharmacol       Date:  1977-03-01       Impact factor: 5.858

6.  Preliminary model for streptozocin metabolism in mice.

Authors:  J M Weissbrod; R K Jain
Journal:  J Pharm Sci       Date:  1980-06       Impact factor: 3.534

7.  Pharmokinetics of 2'-deoxycoformycin in normal and L1210 leukemic mice.

Authors:  W R McConnell; R L Furner; D L Hill
Journal:  Drug Metab Dispos       Date:  1979 Jan-Feb       Impact factor: 3.922

8.  The kinetics of methotrexate distribution in spontaneous canine lymphosarcoma.

Authors:  R J Lutz; R L Dedrick; J A Straw; M M Hart; P Klubes; D S Zaharko
Journal:  J Pharmacokinet Biopharm       Date:  1975-04

9.  Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine (ARA-C) deamination in several species.

Authors:  R L Dedrick; D D Forrester; J N Cannon; S M el-Dareer; L B Mellett
Journal:  Biochem Pharmacol       Date:  1973-10-01       Impact factor: 5.858

10.  Enhancement of the biological activity of adenosine analogs by the adenosine deaminase inhibitor 2'-deoxycoformycin.

Authors:  R H Adamson; D W Zaharevitz; D G Johns
Journal:  Pharmacology       Date:  1977       Impact factor: 2.547

View more
  7 in total

1.  Physiological pharmacokinetic parameters for cis-dichlorodiammineplatinum(II) (DDP) in the mouse.

Authors:  F G King; R L Dedrick
Journal:  J Pharmacokinet Biopharm       Date:  1992-02

2.  Area method for the estimation of partition coefficients for physiological pharmacokinetic models.

Authors:  J M Gallo; F C Lam; D G Perrier
Journal:  J Pharmacokinet Biopharm       Date:  1987-06

3.  Physiologically based pharmacokinetic models of 2',3'-dideoxyinosine.

Authors:  H J Kang; M G Wientjes; J L Au
Journal:  Pharm Res       Date:  1997-03       Impact factor: 4.200

4.  Physiological pharmacokinetic modeling of cis-dichlorodiammineplatinum(II) (DDP) in several species.

Authors:  F G King; R L Dedrick; F F Farris
Journal:  J Pharmacokinet Biopharm       Date:  1986-04

5.  A physiological model for the pharmacokinetics of methylene chloride in B6C3F1 mice following i.v. administrations.

Authors:  M J Angelo; K B Bischoff; A B Pritchard; M A Presser
Journal:  J Pharmacokinet Biopharm       Date:  1984-08

6.  Targeting anticancer drugs to the brain: II. Physiological pharmacokinetic model of oxantrazole following intraarterial administration to rat glioma-2 (RG-2) bearing rats.

Authors:  J M Gallo; P Varkonyi; E E Hassan; D R Groothius
Journal:  J Pharmacokinet Biopharm       Date:  1993-10

7.  Comparative physiological pharmacokinetics of fentanyl and alfentanil in rats and humans based on parametric single-tissue models.

Authors:  S Björkman; D R Wada; D R Stanski; W F Ebling
Journal:  J Pharmacokinet Biopharm       Date:  1994-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.